GSK Signs an Agreement with iTeos to Develop and Commercialize EOS-448 for Patients with Cancer
Shots: iTeos to receive $625M up front & is eligible to receive up to ~$1.45B in milestone upon achievement of certain milestones & royalties on ex-US sales. Both companies will share global development costs of EOS-448 and co-commercialize & share profits in the US GSK to receive an exclusive license for commercialization (Ex-US) & access […]